Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
Status:
Completed
Trial end date:
2021-01-22
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation
study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of
subcutaneously CM310 in moderate-severe AD subjects.